tbuckley/cabot-search huggingface dataset:
Oligoclonal expansion of TCR Vδ T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia
Authors: Zhenyi Jin, Qiang Luo, Shuai Lu, Xinyu Wang, Zifan He, Jing Lai, Shaohua Chen, Lijian Yang, Xiuli Wu, Yangqiu Li
Journal: Journal of Hematology & Oncology (2016)

Recent data have shown that γδ T cells can act as mediators for immune defense against tumors. Our previous study has demonstrated that persisting clonally expanded TRDV4 T cells might be relatively beneficial for the outcome of patients with T cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation (HSCT). However, little is known about the distribution and clonality of the TRDV repertoire in T cell receptor (TCR) of γδ T cells and their effects on the clinical outcome of patients with acute myeloid leukemia (AML). The aim of this study was to assess whether the oligoclonal expansion of TCR Vδ T cells could be used as an immune biomarker for AML outcome. γδ T cells were sorted from the peripheral blood of 30 patients with untreated AML and 12 healthy donors. The complementarity-determining region 3 (CDR3) sizes of eight TCR Vδ subfamily genes (TRDV1 to TRDV8) were analyzed in sorted γδ T cells using RT-PCR and GeneScan. The most frequently expressed TRDV subfamilies in the AML patients were TRDV8 (86.67 %) and TRDV2 (83.33 %), and the frequencies for TRDV1, TRDV3, TRDV4, and TRDV6 were significantly lower than those in healthy individuals. The most frequent clonally expanded TRDV subfamilies in the AML patients included TRDV8 (56.67 %) and TRDV4 (40 %). The clonal expansion frequencies of the TRDV2 and TRDV4 T cells were significantly higher than those in healthy individuals, whereas a significantly lower TRDV1 clonal expansion frequency was observed in those with AML. Moreover, the oligoclones of TRDV4 and TRDV8 were independent protective factors for complete remission. Furthermore, the oligoclonal expansion frequencies of TRDV5 and TRDV6 in patients with relapse were significantly higher than those in non-recurrent cases. To the best of our knowledge, we characterized for the first time a significant alteration in the distribution and clonality of the TRDV subfamily members in γδ T cells sorted from AML patients. Clonally expanded TRDV4 and TRDV8 T cells might contribute to the immune response directed against AML, while oligoclonal TRDV5 and TRDV6 might occur in patients who undergo relapse. While the function of such γδ T cell clones requires further investigation, TRDV γδ T cell clones might be potential immune biomarkers for AML outcome.
FRI0487 Association between Fever Pattern and Clinical Manifestations in Adult Onset of Still's Disease: Unbiased Analysis of Fever Pattern Using Hierarchical Clustering
Authors: E.Y. Ahn, H.M. Kwon, W. Hwang, E.Y. Lee, E.B. Lee, Y.W. Song, J.K. Park
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Adult onset of Still9s disease (AOSD) is a systemic inflammatory disease characterized by fever, arthritis, salmon pink rash and elevated serum inflammatory markers. The classical fever of AOSD is intermittent with a quotidian or double-quotidian pattern. However, a significant subset of AOSD exhibits persistently high fever with little temperature fluctuation. It remains unclear as to whether the certain fever pattern is associated with specific clinical manifestations. <h3>Objectives</h3> To investigate the association between fever pattern and clinical characteristics in patients with AOSD. <h3>Methods</h3> A total of 70 patients with AOSD who were treated as inpatient at Seoul National University Hospital from 2004 through 2015 were enrolled. Patients were grouped based on the fever curves on days 2, 3 and 4 using hierarchical clustering. The clinical and laboratory characteristics of the groups were compared. <h3>Results</h3> 70 patients were divided into 2 groups based on the fever curves. The group 1 with 14 patients had a higher mean temperature (38.1±0.4°C vs. 37.2±0.5°C, p&lt;0.001) with wider daily variation (2.7±0.9°C vs. 1.9±0.7°C, p&lt;0.001) as compared to 56 patients in the group 2. Group 1 tended to be younger (38.4 ± 14.7 years vs. 46.1 ± 17.6 years, p=0.141) (Figure). Fever, arthritis, arthralgia and rash did not differ between them. However, group 1 tended to have more pericardial and lung involvement (42.9% v.s 23.2%, p=0.181). Group 1 had significantly lower platelet count (198,900 ± 68,000/μl vs. 312,900 ± 156,900/μl, p=0.0001), higher LDH (816.6 ± 376.4 IU/L vs. 477.5 ± 327.1 IU/L, p=0.002), higher mean ferritin level (27,004.1 ± 48,891.5 ug/mL vs. 6,852 ± 10,628.2 ug/mL, p=0.072) and d-dimer (9.5 ±7.9 ug/mL vs 3.3 ± 3.4 ug/mL) as compared to group 2, whereas white blood cell count, hemoglobin levels, CRP levels did note differ between the both groups. Group 1 tended to require longer time to a clinical remission (455.5 ± 850 days vs. 9.4 ± 115.7 days, p=0.137). <h3>Conclusions</h3> The unbiased analysis of fever reveals the presence of at least 2 distinctive fever patterns in AOSD. Spiking fever with higher daily variation was more often associated with higher inflammatory markers and coagulopathy and required longer treatment. Thus, fever pattern might be a prognostic factor in AOSD and AOSD patients with spiking fever might need more intensified treatment. <h3>Disclosure of Interest</h3> None declared
Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial
Authors: Yue Gao, Bin Fan, Kha Le, Erika Manyak, Hua Yang, Katherine Yen, Sam Agresta, Eyal C. Attar, Jian Chen, Qiang Xu, Alessandra Tosolini, Jay M. Mei, Anjan Thakurta, Robert D. Knight, Yan Li
Journal: Blood (2015)
A Chimeric Gene, FIP1L1-RARα, Is Isolated from t(4;17)-Positive Acute Promyelocytic Leukemia; a Report of Cloning and Functional Analysis.
Authors: Takeshi Kondo, Akio Mori, Masahiro Onozawa, Kaoru Kahata, Satoshi Hashino, Junji Tanaka, Masahiro Imamura, Masanobu Morioka, Masahiro Asaka
Journal: Blood (2007)
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.
Authors: Paul G Richardson, Sagar Lonial, Andrzej J Jakubowiak, Sundar Jagannath, Noopur S Raje, David E Avigan, Irene Ghobrial, Robert L Schlossman, Amitabha Mazumder, Nikhil C. Munshi, Jacob Laubach, David Vesole, Robin Joyce, Jacalyn Rosenblatt, Wanling Xie, Deborah Doss, Diane L. Warren, Kate Ittleman, Carolyn Revta, Dixil Francis, Charles Leister, Sarah Kaster, Carol Delaney, Marisa Lauria, Constantine S. Mitsiades, Teru Hideshima, Robert Knight, Dixie-Lee Esseltine, Edie Weller, Kenneth C. Anderson
Journal: Blood (2009)
High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study
Authors: Daniela Cilloni, Emanuela Messa, Lucia Biale, Margherita Bonferroni, Flavia Salvi, Monia Lunghi, Bernardino Allione, Dario Ferrero, Roberto Freilone, Alessandro Levis, Giuseppe Saglio
Journal: Blood (2011)
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer. Still hope after the last hope?
Authors: F. Aroldi, P. Bertocchi, T. Prochilo, L. Rota, A. Rizzi, F. Meriggi, B. Di Biasi, C. Abeni, C. Ogliosi, G.D. Beretta, A. Zaniboni
Journal: Annals of Oncology (2015)
Novel Alkylating Agent, Ureidomustine Exhibit Pre-Clinical Efficacy in B-Cell Lymphoma with Minimal Dose-Limiting Myelotoxicity
Authors: Eloisi Caldas Lopes, Shieh Jae-Hung, Srikanth Ambati, Su Tsann-Long, Fabian Correa, Elizabeth Peguero, Malcolm A.S. Moore
Journal: Blood (2015)
PWE-080 Eosinophilic Oesophagitis: Improving Diagnosis and Optimising Therapy
Authors: I Parisi, H Saravanapavan, C Bailey, S Mankodi, A Shah, D Grant, M Rodriguez-Justo, M Novelli, R Sweis
Journal: Gut (2016)

<h3>Introduction</h3> Eosinophilic oesophagitis (EoE) is a chronic condition of the oesophagus characterised by a dense eosinophilic infiltrate defined as &gt;15 eosinophils/high power field (eos/hpf). The aim of this study was to capture the prevalence of EoE in a tertiary referral centre in London, to identify factors associated with a positive diagnosis and interrogate optimal response to therapy. <h3>Methods</h3> From February 2013 to November 2015, all patients presenting with solid food dysphagia to University College Hospital had a high resolution white light endoscopy. Those with cancer, achalasia, postoperative stricture or endotherapy for Barrett’s were excluded. Endoscopy, histology and clinical data were collected. &gt;15 oes/hpf were defined as positive for EoE. A separate histopathology search identified patients with &gt;15 eos/hpf and no dysphagia. A prospective follow-up was conducted in focusing on therapy and response in those with &gt;15 eos/hpf. <h3>Results</h3> Out of the 1566 patients with dysphagia, 524 were excluded for reasons stated. 736/1042 (71%) had oesophageal biopsies. Of those, 67 (9.1%) had more than 15 eos/hpf. Another 14 patients with &gt;15 eos/hpf with symptoms other than dysphagia were identified from histology records, making the total number with eosiniphilia 81. The mean number of biopsies taken in those with &gt;15 eos/hpf (6.3) was greater than those with &lt;15 eos/hpf (5.1; p = 0.003). EoE patients were more likely to be male (70%) and younger (43±16 years) compared to nonEoE (40% male, p &lt; 0.0001; 59±16 years, p &lt; 0.0001). Typical endoscopic features were found in 39 (48%) EoE patients; rings/furrows in 26 (32%) and strictures in 15 (18%). 42/81 (52%) were treated with PPIs only of which 19 (45%) clinically responded. 18 (22%) patients had both PPI and topical steroids (12 had steroids after PPI failure) while 8/81 (10%) had steroids only. Clinically 14/26 (54%) responded optimally to topical steroids, 13 of which had dysphagia. Overall, response to steroids occurred in those with a higher eosinophilia (53 vs 24, p = 0.004) and all 9 with ≥40 eos/hpf had a complete response. Furthermore, typical EoE findings at endoscopy was more likely to be associated with a poor response to PPIs (p &lt; 0.0001). <h3>Conclusion</h3> A higher number of biopsies taken raises the diagnostic yield; however still up to 1/3 patients in a modern referral centre have no biopsies taken. EoE should be excluded in those with no dysphagia and refractory reflux symptoms. Although PPIs are provided as first-line therapy, a positive response to steroids is more likely in those with higher numbers eos/hpf, while those with fewer numbers and no endoscopic features could be considered for PPI therapy first. Such findings might be a useful tool to help tailor therapy. <h3>Disclosure of Interest</h3> None Declared
Prophylactic Use of Sorafenib in Patients with FLT3-ITD-Positive Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Qifa Liu, Li Xuan, Zhiping Fan, Qianli Jiang, Min Dai, Pengcheng Shi, Changxin Yin, Jing Sun
Journal: Blood (2014)
Clinical Features, Outcomes and Prognosis of Oropharyngeal Lymphoma: An Analysis from the Thai Lymphoma Study Group (TLSG)
Authors: Kanchana Chansung, Chittima Sirijerachai, Arnuparp Lekhakula, Jakrawadee Julamanee, Lalita Norasetthada, Weerasak Nawarawong, Archrob Khuhapinant, Supachai Ekwattanakit, Kitsada Wudhikarn, Udomsak Bunworasate, Suporn Chuncharunee, Pimjai Niparuck, Tontanai Numbenjapon, Kannadit Prayongratana, Tawatchai Suwanban, Somchai Wongkhantee, Peerapon Wong, Nisa Makruasi, Nonglak Kanitsap, Tanin Intragumtornchai
Journal: Blood (2015)
PCSM-06COMPARISON OF THE SYMPTOM BURDEN IN ACTIVE TREATMENT VERSUS FOLLOW-UP FOR PRIMARY BRAIN TUMOR PATIENTS
Authors: Anna Leisy, Terri Armstrong, Avlina Acquaye, Elizabeth Vera-Bolanos, Mark Gilbert, Stanley Cron
Journal: Neuro-Oncology (2015)

BACKGROUND: Primary Brain Tumor (PBT) patients have unique symptoms compared with patients with systemic cancers, likely related to involvement of the central nervous system. Despite aggressive treatment, declaration of true remission is difficult because of the high rate of recurrence. The purpose of this study was to compare the symptom experience of patients in follow-up with those undergoing active treatment. METHODS: Cross-sectional patient-reported outcome symptom data (M.D. Anderson Symptom Inventory-Brain Tumor) measuring both core oncology and PBT-specific symptoms was collected. Active-treatment and follow-up groups were compared for each of 22 symptom items in terms of symptom severity, number of symptoms and differences in overall severity. Six functional symptom groupings and group differences were assessed with linear regression. FINDINGS: The sample included 488 patients (273 on active treatment; 215 follow-up). The on-treatment group was significantly older [48.83 years (18-79) vs 44.46 years (18-84)] and more likely to have a glioblastoma (p < 0.0001). Mean symptom severity was not significantly different between groups [on-treatment 1.64 (0-7.36), follow-up 1.57 (0-6.36), p = 0.5747]. Patients on treatment reported higher symptom prevalence for 8 of 22 items. They reported more moderate/severe nausea (p = 0.0409) and bowel problems (p = 0.0029), with higher aggregate general symptom (p = 0.0044) and GI symptom (p = 0.0044) scores. After adjusting for age and KPS, the number of symptoms were not different between groups (p = 0.2346), but general (p = 0.0407) and GI (0.0056) symptoms were more severe in those on active treatment. CONCLUSION: This preliminary analysis shows that PBT patients on active treatment have more severe treatment-associated symptoms. However, patients in follow-up have disease-related symptoms, number of symptoms and overall symptom burden as severe as those on treatment. These findings underscore the need for disease-related symptom management for both groups and additional research to determine factors that explain symptom pattern over the course of the disease.
PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma
Authors: Owen A. O’Connor, Barbara Pro, Lauren Pinter-Brown, Leslie Popplewell, Nancy Barlett, Andrei Shustov, Mary Jo Lechowicz, Kerry J Savage, Bertrand Coiffier, Eric Jacobsen, Pier Luigi Zinzani, Andre Goy, Jasmine Zain, Shannon Wilroy, Molly Patterson, Adam Boyd, Michael E. Saunders, Pablo Cagnoni, Steven M. Horwitz
Journal: Blood (2008)
A Specific DNA Methylation Pattern Is Associated with Delayed Leukemogenesis and Altered Response to Chemotherapeutic Treatment in an Inducible DNMT3b Expressing Mouse Model
Authors: Isabell Schulze, Petra Tschanter, Christian Rohde, Nicole Baeumer, Heinz Linhart, Katja Hebestreit, Wolfgang E. Berdel, Martin Dugas, Carsten Müller-Tidow
Journal: Blood (2012)
Treosulfan, Etoposide and Cyclophosphamide as Non TBI-Conditioning Regimen Followed by Allogeneic SCT for Acute Lymphoblastic Leukemia
Authors: Nicolaus Kröger, Matthias Stelljes, Martin Bornhäuser, Wolfgang A. Bethge, Renate Arnold, Hans Martin, Christoph Schmid, Karin Kolbe, Nicola Goekbuget, Dieter Hoelzer, Axel R. Zander, Dietrich Beelen
Journal: Blood (2010)
Is delamanid a potential agent in the treatment of diseases caused by<i>Mycobacterium avium-intracellulare</i>?
Authors: David Krieger, Nicolas Schönfeld, Silvan Vesenbeckh, Gudrun Bettermann, Torsten Thomas Bauer, Holger Rüssmann, Harald Mauch
Journal: European Respiratory Journal (2016)

Delamanid, a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis, has strong in vitro activity against Mycobacterium tuberculosis , including multidrug resistant (MDR) strains [1]. The drug has been proven to be effective in treatment of MDR tuberculosis (MDR-TB) patients [2–5]. Delamanid is pharmacologically characterised by an excellent intracellular bactericidal activity and a high accumulation rate [6]. Delamanid shows low minimal inhibitory concentrations in vitro against M. avium-intracellulare strains <http://ow.ly/xDiM304ul7O>
THU0338 Cystic Lung Disease in Sjögren's Syndrome: An Observational Study
Authors: S. Lechtman, M.-P. Debray, B. Crestani, C. Bancal, M. Hourseau, A. Dossier, J.-F. Alexandra, M.-P. Chauveheid, T. Papo, K. Sacre
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Assessments of the prevalence of pulmonary involvement in Sjögren9s syndrome (SS) vary considerably in the literature. Moreover some publications found that lung involvement in SS is usually mild and stable while others describe a far more severe disease complication with a 5-year mortality of more than 15%. This is indicating that more studies of prevalence and severity of pulmonary involvement in SS are needed <h3>Objectives</h3> To analyze the prevalence, characteristics and outcome of cystic lung disease associated with Sjögren9s syndrome (SS). <h3>Methods</h3> From June 2010 to February 2015, 90 SS patients (60.1±14.8 years; 88 (97.8%) female, 62 (68.9%) primary SS) had a systematic chest CT-scan. The presence of thin-walled cysts was analyzed by one experienced radiologist. Demographic data, clinical history, laboratory findings, and pulmonary function tests were extracted from medical records. <h3>Results</h3> Twenty-one (23.3%) patients had cysts on CT scan performed 40.5±54.5 months after SS diagnosis. Cysts number ranged from 1 to 25, were often bilateral (52.4%) and mostly located in the middle lung zone (76.2%). Cysts were isolated (n=6, 28.6%) or associated with other lesions including bronchiectasis (n=5, 23.8%), micronodules (n=5, 23.8%), ground-glass opacity (n=4, 19%) and/or air trapping (n=3, 14.3%). Most patients with cysts (57.1%) had no respiratory symptoms. When comparing SS patients with and without cysts, patients with cysts tended to be older (65.3±15.3 versus 58.5±14.4 years, p=0.06). Smoking habits were similar in both groups. Anti-SSB antibodies were more frequently detected in patients with cysts (57.1% vs 26.1%, p=0.02). Pulmonary function tests were normal in most cases (52.6%) or displayed only mild small airways obstruction and reduced diffusion capacity to carbon monoxide. Four (19%) patients with cysts had a past history of associated pulmonary disease including interstitial lung disease. During follow-up (25.1±17.7 months) no patient developed specific lung disease or lymphoproliferative disorders. <h3>Conclusions</h3> Cystic lung disease is frequent, benign, associated with anti-SSB/La antibodies and has no impact on outcome in SS <h3>Disclosure of Interest</h3> None declared
Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis
Authors: Homare Eda, Loredana Santo, Diana D. Cirstea, Samantha Pozzi, Miriam Canavese, Tyler A. Scullen, Sonia Vallet, Noopur S. Raje
Journal: Blood (2011)
Activation of DR3 Signaling Expands Recipient Derived Regulatory T Cells and Enhances Donor Immune Reconstitution Derived from Allogeneic Hematopoietic Stem Cells
Authors: Hidekazu Nishikii, Byung Su Kim, Antonio Pierini, Jeanette Baker, Dominik Schneidawind, Yuqiong Pan, Maite Alvarez, Robert S. Negrin
Journal: Blood (2014)
Kinetics of Self-Renewal and Differentiation Divisions of Transplanted Hematopoietic Stem and Progenitor Cells Early After Transplantation Into Lethally-Irradiated Recipients.
Authors: Hui Lin Chua, Vikram Anand, Carol Sampson, Ngoc-Thinh Nguyen, Artur Plett, Evan West, Christie M. Orschell
Journal: Blood (2009)
PWE-146 Is A Nurse-Led Computerised HCC Surveillance System Effective?: Abstract PWE-146 Table 1
Authors: S Priestley, S Testrow, K Ashton, J Jones, M Fox
Journal: Gut (2016)

<h3>Introduction</h3> Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers and has a growing incidence of HCC worldwide. In 2013, liver cancer accounted for 2% of all cancers with an incidence of 5,413 new cases. 90–95% of cases of HCC arise in cirrhosis and non-cirrhotic chronic Hepatitis B.<sup>1</sup> Outcomes are poor with a median survival of 11 months and a 3 year survival rate of 19%.<sup>2</sup> Factors influencing outcome are multifactorial but evidence supports improved results through screening high risk groups. The British Society of Gastroenterology (BSG) guidelines on the surveillance of HCC in high risk groups recommend 6 monthly liver ultrasound (USS) and serum alpha fetoprotein (AFP). The ad hoc nature of our HCC surveillance contributed to the expansion of our liver service, including 2 liver specialist nurses and an electronic HCC surveillance database, all designed to provide a more robust system. The database includes appropriate patients and automatically flags up when surveillance is due. Has this service development had an impact of on patient care? <h3>Methods</h3> A retrospective audit compares surveillance over 2 time periods: before and after the introduction of the database in January 2015. Data was obtained from the database and patient records. Deceased patients or those removed from the programme on clinical grounds were excluded from the cohorts. The following data was collected: gender, age, aetiology, CPS, date of diagnosis and the time interval between serum AFP measurements and liver imaging. <h3>Results</h3> There is no significant difference in demographics between the 2 cohorts. The table below illustrates the percentages of patients undergoing surveillance within the guidelines. HCC was diagnosed in 5 patients (2 pre/3 post group) with a mean AFP of 13 mcg/l at diagnosis. <h3>Conclusion</h3> Establishment of the database and the specialist nurse service has improved data collection reflected in the increased numbers undergoing surveillance. There is improved compliance, with detection &amp; treatment of early HCC. Any delays were often due to patient cancellation, occasionally repeatedly, without a subsequent appointment being immediately arranged. So how could we improve further still? Recommendations may include; a cancellation failsafe mechanism, increased patient education with comprehensive information leaflet and more intelligent software that automatically sends an electronic reminder, as currently the database still relies on manual monitoring. <h3>References</h3> 1 Forner A, <i>et al</i>. Hepatocellular carcinoma. <i>Lancet</i> 2012 March;<b>379</b>(9822):1245–55. 2 Greten TF, <i>et al</i>. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. <i>Br J Cancer</i> 2005 May;<b>92</b>(10):1862–1868. <h3>Disclosure of Interest</h3> None Declared
High-Dose Therapy Followed by Autologous HSCT in Patients with Multiple Myeloma. Results of a Retrospective Multicenter Analysis Conducted by The Polish Myeloma Group.
Authors: Wanda M. Knopinska-Posluszny, Andrzej Hellmann, Michal Taszner, Anna Dmoszynska, Wiktor Jedrzejczak, Jerzy Holowiecki, Jan Walewski, Krzysztof Warzocha, Aleksander Skotnicki, Andrzej Lange, Kazimierz Kuliczkowski, Kazimierz Sulek, M. Komarnicki, Tadeusz Robak
Journal: Blood (2007)